Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Leukemia, Lymphocytic, Chronic, B-Cell"" wg kryterium: Temat


Tytuł :
High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia.
Autorzy :
Helaly NA; Department of Medical Laboratory Technology, Faculty of Applied Health Sciences, Pharos University, Alexandria, Egypt.
Esheba NE; Department of Internal Medicine, Hematology Unit, Faculty of Medicine, Tanta University, Egypt. Electronic address: .
Ammo DEA; Department of Clinical Pathology, Faculty of Medicine, Tanta University, Egypt.
Elwan NM; Department of Clinical Pathology, Faculty of Medicine, Tanta University, Egypt.
Elkholy RA; Department of Clinical Pathology, Faculty of Medicine, Tanta University, Egypt.
Pokaż więcej
Źródło :
Leukemia research [Leuk Res] 2021 Aug; Vol. 107, pp. 106604. Date of Electronic Publication: 2021 Apr 30.
Typ publikacji :
Journal Article
MeSH Terms :
Biomarkers, Tumor*
Leukemia, Lymphocytic, Chronic, B-Cell/*metabolism
Leukemia, Lymphocytic, Chronic, B-Cell/*mortality
Proto-Oncogene Proteins c-bcl-2/*metabolism
bcl-2-Associated X Protein/*metabolism
Humans ; Immunophenotyping ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/etiology ; Neoplasm Staging ; Prognosis ; Proto-Oncogene Proteins c-bcl-2/genetics ; ROC Curve ; bcl-2-Associated X Protein/genetics
Czasopismo naukowe
Tytuł :
Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.
Autorzy :
Elnair R; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, 68198, USA. .
Ellithi M; Department of Internal Medicine, Sanford School of Medicine, University of South Dakota, Vermillion, SD, USA.
Kallam A; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Shostrom V; College of Public Health, Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA.
Bociek RG; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Oct; Vol. 100 (10), pp. 2513-2519. Date of Electronic Publication: 2021 Jul 19.
Typ publikacji :
Journal Article
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell/*pathology
Aged ; Cell Transformation, Neoplastic/pathology ; Disease Progression ; Female ; Hodgkin Disease/diagnosis ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/complications ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Male ; Middle Aged ; Prognosis
Czasopismo naukowe
Tytuł :
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
Autorzy :
Cuneo A; Hematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Rigolin GM; Hematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Coscia M; Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.
Quaresmini G; USC Ematologia, ASST Papa Giovanni XXIII, Bergamo, Italy.
Scarfò L; Università Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy.
Mauro FR; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
Motta M; S.C. Ematologia, ASST Spedali Civili, Brescia, Italy.
Quaglia FM; Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Trentin L; Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, Italy.
Ferrario A; UOC Ematologia Azienda Socio Sanitaria Territoriale dei Sette Laghi, Ospedale di Circolo di Varese, Varese, Italy.
Laurenti L; Hematology, Fondazione Universitaria Policlinico A. Gemelli, Rome, Italy.
Reda G; U.O.C. Ematologia, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy.
Ferrari A; Hematology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Pietrasanta D; Division of Hematology, SC di Ematologia, Ospedale Civile SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Sportoletti P; Department of Medicine and Surgery, Institute of Hematology and Center for Hemato-Oncological Research, Ospedale S. Maria della Misericordia, Perugia, Italy.
Re F; Hematology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
De Paoli L; SCDU Ematologia AOU Maggiore della Carità, Novara, Italy.
Foglietta M; SC Ematologia Azienda Ospedaliera Santa Croce e Carle, Cuneo, Italy.
Giordano A; Hematology-Department of Emergency and Organ Transplantation, Azienda Ospedaliero Universitaria Policlinico, Bari, Italy.
Marchetti M; Hematology-Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo Alessandria, Alessandria, Italy.
Farina L; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Del Poeta G; Hematology, S. Eugenio Hospital, University of Tor Vergata, Rome, Italy.
Varettoni M; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Chiurazzi F; Hematology Unit, University of Naples Federico II, Naples, Italy.
Marasca R; Hematology Unit, University of Modena and Reggio Emilia, Modena, Italy.
Malerba L; UOC Ematologia e Centro trapianti AORMN Pesaro, Pesaro, Italy.
Ibatici A; Hematology and Bone Marrow Transplant, Policlinico San Martino, Genova, Italy.
Tisi MC; Hematology, Azienda ULSS 8 Berica Dipartimento Strutturale Oncologia Clinica Vicenza, Vicenza, Italy.
Stefoni V; Department of Hematology and Oncology 'L. and A. Seràgnoli', Bologna, Italy.
Leone M; Hematology, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.
Baratè C; Clinical and Experimental Medicine, Hematology Section, University of Pisa, Pisa, Italy.
Olivieri J; Hematology Unit, Azienda Ospedaliero Universitaria Santa Maria della Misericordia, Udine, Italy.
Murru R; SC Ematologia e CTMO Ospedale Oncologico A. Businco, ARNAS 'G. Brotzu', Cagliari, Italy.
Gentile M; UOC Ematologia AO Cosenza, Cosenza, Italy.
Sanna A; Hemtology Unit, Azienda Ospedaliero Universitaria Careggi Firenze, Firenze, Italy.
Gozzetti A; Hematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese Siena, Siena, Italy.
Gattei V; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Gottardi D; SCDU Ematologia Ospedale Mauriziano, Torino, Italy.
Derenzini E; Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
Levato L; SOC Ematologia, Dipartimento di Ematologia Oncologia Azienda Ospedaliera Pugliese Ciaccio Catanzaro, Catanzaro, Italy.
Orsucci L; SC Ematologia, AUO Città della Scienza e della Salute di Torino, Torino, Italy.
Penna G; UOC Ematologia Policlinico Universitario di Messina, Messina, Italy.
Chiarenza A; Divisione di Ematologia con Trapianto di Midollo Osseo, Azienda Ospedaliera Universitaria Policlinico 'G.Rodolico-S.Marco', Catania, Italy.
Foà R; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2021 Oct; Vol. 39 (4), pp. 570-574. Date of Electronic Publication: 2021 Jul 13.
Typ publikacji :
Letter
MeSH Terms :
COVID-19/*complications
Leukemia, Lymphocytic, Chronic, B-Cell/*therapy
SARS-CoV-2/*immunology
Vaccination/*methods
Aged ; COVID-19/prevention & control ; COVID-19/transmission ; COVID-19/virology ; Disease Management ; Female ; Humans ; Italy/epidemiology ; Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology ; Leukemia, Lymphocytic, Chronic, B-Cell/virology ; Male ; Middle Aged ; Prognosis ; Time Factors
Opinia redakcyjna
Tytuł :
Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death.
Autorzy :
Rotbain EC; Department of Hematology, Odense University Hospital, Odense, Denmark. .; Department of Hematology, Rigshospitalet, Copenhagen, Denmark. .; Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark. .; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. .
Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Rostgaard K; Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
da Cunha-Bang C; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Hjalgrim H; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.; Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.
Frederiksen H; Department of Hematology, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Sep; Vol. 35 (9), pp. 2570-2580. Date of Electronic Publication: 2021 Feb 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell/*epidemiology
Leukemia, Lymphocytic, Chronic, B-Cell/*mortality
Aged ; Aged, 80 and over ; Cause of Death ; Combined Modality Therapy ; Comorbidity ; Denmark/epidemiology ; Female ; Follow-Up Studies ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/therapy ; Male ; Middle Aged ; Prognosis ; Survival Rate
Czasopismo naukowe
Tytuł :
Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).
Autorzy :
Lazarian G; Laboratoire d'hématologie, Hôpital Avicenne - INSERM U978- Université Paris Sorbonne Nord, Bobigny, France.
Munger M; Hématologie, CHU de Québec - Hôpital de l'Enfant-Jésus, Québec City, Québec, Canada.
Quinquenel A; Service d'hématologie, CHU de Reims, Hôpital Robert-Debré, Université Reims Champagne-Ardenne, Reims, France.
Dilhuydy MS; Service d'hématologie clinique et thérapie cellulaire, CHU Bordeaux - Groupe Sud (Hôpital Haut-Lévèque), Bordeaux, France.
Veronese L; Cytogénétique Médicale Hématologie-Oncologie, CHU Estaing, Clermont-Ferrand, France.
Luque Paz D; Laboratoire d'hématologie, CHU d'Angers, Angers, France.
Guièze R; Service de thérapie cellulaire et hématologie clinique, CHU de Clermont Ferrand, Clermont-Ferrand, France.
Ledoux-Pilon A; Anatomie Pathologique, CHU Estaing, Clermont-Ferrand, France.
Paillassa J; Service d'hématologie, CHU d'Angers, Angers, France.
Merabet F; Service d'hématologie, Hôpital de Versailles, Université Versailles, Saint Quentin, France.
Vial JP; Laboratoire d'hématologie, CHU Bordeaux - Groupe Sud (Hôpital Haut-Lévèque), Bordeaux, France.
Bidet A; Laboratoire d'hématologie, CHU Bordeaux - Groupe Sud (Hôpital Haut-Lévèque), Bordeaux, France.
Waultier Rascalou A; Hématologie clinique, CHU Nîmes Caremeau Institut de Cancerologie du Gard, Nîmes, France.
Broseus J; Laboratoire d'hématologie, CHRU de Nancy, Vandoeuvre-lès-Nancy, France.
Roos-Weil D; Sorbonne Université, Service d'hématologie clinique, GH Pitie- Salpêtrière, Paris, France.
Lavaud A; Sorbonne Université, Service d'hématologie clinique, GH Pitie- Salpêtrière, Paris, France.
Molina L; Service d'hématologie, CHU de Grenoble, Grenoble, France.
Laribi K; Service d'hématologie, CH Le Mans, Le Mans, France.
Hivert B; Hématologie clinique, Groupement des Hôpitaux de l'Institut Catholique de Lille Hôpital St Vincent de Paul, Lille, France.
Friedrich C; Laboratoire d'hématologie, Hôpital Cochin, Paris, France.
Carpentier B; Laboratoire d'hématologie, Hôpital Cochin, Paris, France.
Ysebaert L; Hématologie clinique, Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole, Toulouse, France.
Van Den Neste E; Hématologie, Cliniques universitaires UCL Saint-Luc, Bruxelles, Belgium.
Willems L; Hématologie clinique, Hôpital Cochin, Paris, France.
Corby A; Service d'oncologie hématologie, Groupe hospitalier la Rochelle Hématologie Adulte, La Rochelle, France.
Poulain S; Hematology Laboratory, Biology and Pathology Center, CHU de Lille, Lille, France.
Eclache V; Laboratoire d'hématologie, Hôpital Avicenne - INSERM U978- Université Paris Sorbonne Nord, Bobigny, France.
Maubec E; Service de Dermatologie, Hôpital Avicenne, Bobigny, France.
Martin A; Laboratoire d'anatomocytopathologie, Hôpital Avicenne, Bobigny, France.
Feugier P; Département d'hématologie, CHRU de Nancy, Vandoeuvre-lès-Nancy, France.
Delmer A; Service d'hématologie, CHU de Reims, Hôpital Robert-Debré, Université Reims Champagne-Ardenne, Reims, France.
Baran-Marszak F; Laboratoire d'hématologie, Hôpital Avicenne - INSERM U978- Université Paris Sorbonne Nord, Bobigny, France.
Leprêtre S; Département d'Hématologie, Centre Henri Becquerel, Normandie université UNIROUEN, Rouen, France.
Cymbalista F; Laboratoire d'hématologie, Hôpital Avicenne - INSERM U978- Université Paris Sorbonne Nord, Bobigny, France.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 Sep 01; Vol. 96 (9), pp. E353-E356. Date of Electronic Publication: 2021 Jul 01.
Typ publikacji :
Letter
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell/*pathology
Skin/*pathology
Skin Neoplasms/*pathology
Adult ; Aged ; Aged, 80 and over ; B-Lymphocytes/pathology ; Female ; France/epidemiology ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Male ; Middle Aged ; Mutation ; Skin Neoplasms/epidemiology ; Skin Neoplasms/genetics ; Treatment Outcome
Opinia redakcyjna
Tytuł :
Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.
Autorzy :
Kovalovsky D; Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA. .
Yoon JH; Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Cyr MG; Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, 33458, USA.
Simon S; Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Voynova E; Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Rader C; Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, 33458, USA.
Wiestner A; Laboratory of Lymphoid Malignancies, National Heart, Lung and Blood Institute. NIH, Bethesda, MD, 20892, USA.
Alejo J; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Pittaluga S; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Gress RE; Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Sep; Vol. 35 (9), pp. 2581-2591. Date of Electronic Publication: 2021 Feb 25.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
MeSH Terms :
Hematopoietic Stem Cell Transplantation/*methods
Immunotherapy, Adoptive/*methods
Lectins/*antagonists & inhibitors
Leukemia, Lymphocytic, Chronic, B-Cell/*therapy
Receptors, Chimeric Antigen/*immunology
Animals ; Antigens, CD/immunology ; Antigens, Differentiation, Myelomonocytic/immunology ; Cell Proliferation ; Combined Modality Therapy ; Humans ; Lectins/immunology ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
Autorzy :
Roeker LE; Memorial Sloan Kettering Cancer Center, New York, NY, USA. .
Knorr DA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Thompson MC; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nivar M; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lebowitz S; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Peters N; Memorial Sloan Kettering Cancer Center, Basking Ridge, NJ, USA.
Deonarine I Jr; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Momotaj S; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sharan S; Memorial Sloan Kettering Cancer Center, Commack, NY, USA.
Chanlatte V; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hampton B; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Butala L; Memorial Sloan Kettering Cancer Center, Basking Ridge, NJ, USA.
Amato L; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Richford A; Memorial Sloan Kettering Cancer Center, Commack, NY, USA.
Lunkenheimer J; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Battiato K; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Laudati C; Memorial Sloan Kettering Cancer Center, Basking Ridge, NJ, USA.
Mato AR; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Sep; Vol. 35 (9), pp. 2703-2705. Date of Electronic Publication: 2021 May 13.
Typ publikacji :
Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
COVID-19/*drug therapy
COVID-19 Vaccines/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*immunology
SARS-CoV-2/*drug effects
Adult ; Aged ; COVID-19/immunology ; COVID-19/pathology ; COVID-19/virology ; COVID-19 Vaccines/immunology ; Female ; Humans ; Immunity ; Immunocompromised Host ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Leukemia, Lymphocytic, Chronic, B-Cell/virology ; Male ; Middle Aged ; SARS-CoV-2/immunology
Raport
Tytuł :
Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.
Autorzy :
Tadmor T; Hematology Unit, Bnai Zion Medical Center, Haifa, Israel.; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Benjamini O; Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel. Tamar.tadmor@b-zion.org.il.; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Tamar.tadmor@b-zion.org.il.
Braester A; Department of Hematology, Galilee Medical Center, Nahariya, Israel.
Rahav G; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; The Infectious Disease Unit, Sheba Medical Center, Tel-Hashomer, Israel.
Rokach L; Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Sep; Vol. 35 (9), pp. 2727-2730. Date of Electronic Publication: 2021 Aug 10.
Typ publikacji :
Letter
MeSH Terms :
Antibodies, Viral/*immunology
COVID-19/*drug therapy
COVID-19 Vaccines/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*immunology
Adult ; Aged ; Aged, 80 and over ; Antibodies, Viral/blood ; Antibody Formation ; COVID-19/complications ; COVID-19/virology ; Case-Control Studies ; Female ; Follow-Up Studies ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/blood ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/virology ; Longitudinal Studies ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; SARS-CoV-2/isolation & purification
Opinia redakcyjna
Tytuł :
Prognostic factors for clinical outcomes of patients with central nervous system leukemia.
Autorzy :
Bharucha J; University of Minnesota Medical School, Minneapolis, MN, USA.
Cao Q; Biostatistics and Bioinformatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Sachs Z; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Smith A; Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Williams S; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Amin K; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Bachanova V; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Warlick E; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Brunstein C; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Weisdorf D; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Bejanyan N; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA. Electronic address: .
Pokaż więcej
Źródło :
Hematology/oncology and stem cell therapy [Hematol Oncol Stem Cell Ther] 2021 Sep; Vol. 14 (3), pp. 240-245. Date of Electronic Publication: 2020 Nov 24.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Central Nervous System Neoplasms*/diagnosis
Central Nervous System Neoplasms*/mortality
Central Nervous System Neoplasms*/therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell*/mortality
Leukemia, Lymphocytic, Chronic, B-Cell*/therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Stem Cell Transplantation*
Adolescent ; Adult ; Age Factors ; Aged ; Allografts ; Child ; Child, Preschool ; Disease-Free Survival ; Female ; Humans ; Infant ; Male ; Middle Aged ; Retrospective Studies ; Risk Factors ; Survival Rate
Czasopismo naukowe
Tytuł :
Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer.
Autorzy :
Besson C; Service d'hématologie et Oncologie, Centre Hospitalier de Versailles, Le Chesnay; Université Paris-Saclay, UVSQ, Inserm, Équipe 'Exposome et Hérédité', CESP, 94805, Villejuif, France.
Moore A; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Wu W; Department of Medical and Molecular Genetics, Indiana University School of Medicine, USA.
Vajdic CM; Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia.
de Sanjose S; CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Camp NJ; Department of Internal Medicine and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.
Smedby KE; Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Shanafelt TD; Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Morton LM; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Brewer JD; Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
Zablotska L; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Engels EA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Cerhan JR; Service d'hématologie et Oncologie, Centre Hospitalier de Versailles, Le Chesnay; Université Paris-Saclay, UVSQ, Inserm, Équipe 'Exposome et Hérédité', CESP, 94805, Villejuif, France.
Slager SL; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Han J; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Berndt SI; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Pokaż więcej
Corporate Authors :
InterLymph Consortium. Full authors list is given at the end of the manuscript
Źródło :
International journal of epidemiology [Int J Epidemiol] 2021 Aug 30; Vol. 50 (4), pp. 1325-1334.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Basal Cell*/epidemiology
Carcinoma, Basal Cell*/genetics
Carcinoma, Squamous Cell*/epidemiology
Carcinoma, Squamous Cell*/genetics
Leukemia, Lymphocytic, Chronic, B-Cell*/epidemiology
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Skin Neoplasms*/epidemiology
Skin Neoplasms*/genetics
Humans ; Polymorphism, Single Nucleotide ; Risk Factors
Czasopismo naukowe
Tytuł :
A POLE Splice Site Deletion Detected in a Patient with Biclonal CLL and Prostate Cancer: A Case Report.
Autorzy :
Steiner M; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.
Gassner FJ; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.
Parigger T; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.; Department of Biosciences, Paris-Lodron-University Salzburg, 5020 Salzburg, Austria.
Neureiter D; Institute of Pathology, Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.
Egle A; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.
Geisberger R; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.
Greil R; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.
Zaborsky N; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Aug 30; Vol. 22 (17). Date of Electronic Publication: 2021 Aug 30.
Typ publikacji :
Case Reports
MeSH Terms :
Alternative Splicing*
Polymorphism, Single Nucleotide*
DNA Polymerase II/*genetics
Leukemia, Lymphocytic, Chronic, B-Cell/*pathology
Poly-ADP-Ribose Binding Proteins/*genetics
Prostatic Neoplasms/*pathology
Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/complications ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Male ; Middle Aged ; Prognosis ; Prostatic Neoplasms/complications ; Prostatic Neoplasms/genetics
Raport
Tytuł :
Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL.
Autorzy :
Aslan B; Department of Experimental Therapeutics.
Kismali G; Department of Experimental Therapeutics.
Chen LS; Department of Experimental Therapeutics.
Iles LR; Department of Experimental Therapeutics.
Mahendra M; TRACTION Platform, Therapeutics Discovery Division.
Peoples M; TRACTION Platform, Therapeutics Discovery Division.
Gagea M; Department of Veterinary Medicine and Surgery.
Fowlkes NW; Department of Veterinary Medicine and Surgery.
Zheng X; Department of Bioinformatics and Computational Biology, and.
Wang J; Department of Bioinformatics and Computational Biology, and.
Vellano CP; TRACTION Platform, Therapeutics Discovery Division.
Marszalek JR; TRACTION Platform, Therapeutics Discovery Division.
Bertilaccio MTS; Department of Experimental Therapeutics.
Gandhi V; Department of Experimental Therapeutics.; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Pokaż więcej
Źródło :
Blood advances [Blood Adv] 2021 Aug 24; Vol. 5 (16), pp. 3134-3146.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Adenine/analogs & derivatives ; Agammaglobulinaemia Tyrosine Kinase ; Animals ; Humans ; Mice ; Piperidines ; Pyrazoles/pharmacology ; Pyrimidines/pharmacology
Czasopismo naukowe
Tytuł :
EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4 T cells in chronic lymphocytic leukemia.
Autorzy :
Roessner PM; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Llaó Cid L; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany.
Lupar E; Max-Planck-Institute of Immunobiology and Epigenetics, Freiburg, Germany.; Cellzome, Heidelberg, Germany.
Roider T; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany.
Bordas M; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany.
Schifflers C; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Cell Biology Research Unit (URBC)-Namur Research Institute of Life Science (Narilis), University of Namur, Namur, Belgium.; Immunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Arseni L; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Gaupel AC; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Kilpert F; Max-Planck-Institute of Immunobiology and Epigenetics, Freiburg, Germany.; Essen University Hospital, Institute of Human Genetics, Genome Informatics, Essen, Germany.
Krötschel M; Max-Planck-Institute of Immunobiology and Epigenetics, Freiburg, Germany.; BioMed X Institute, Heidelberg, Germany.
Arnold SJ; Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.
Sellner L; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany.
Colomer D; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hematopathology Unit, Hospital Clinic, CIBERONC, Barcelona, Spain.
Stilgenbauer S; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
Dietrich S; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany.
Lichter P; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Izcue A; Max-Planck-Institute of Immunobiology and Epigenetics, Freiburg, Germany.; Center for Chronic Immunodeficiency, University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.; Institute of Molecular Medicine, University Hospital RWTH Aachen, Aachen, Germany.
Seiffert M; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Aug; Vol. 35 (8), pp. 2311-2324. Date of Electronic Publication: 2021 Feb 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CD4-Positive T-Lymphocytes/*immunology
Interleukin-10/*metabolism
Leukemia, Lymphocytic, Chronic, B-Cell/*prevention & control
T-Box Domain Proteins/*metabolism
T-Lymphocytes, Cytotoxic/*immunology
T-Lymphocytes, Regulatory/*immunology
Th1 Cells/*immunology
Animals ; Cell Differentiation ; Female ; Gene Expression Regulation, Leukemic ; Humans ; Interferon-gamma ; Interleukin-10/genetics ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Mice ; Mice, Inbred C57BL ; Prognosis ; Signal Transduction ; T-Box Domain Proteins/genetics ; Transcriptome ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.
Autorzy :
Maffei R; Hematology Division, Department of Oncology and Hematology, A.O.U of Modena-Policlinico, Modena, Italy.
Fiorcari S; Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Atene CG; Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Martinelli S; Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Scarfò L; Division of Experimental Hematology, Laboratory of B cell Neoplasia, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy.
Bonfiglio S; Division of Experimental Hematology, Laboratory of B cell Neoplasia, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy.
Maccaferri M; Hematology Division, Department of Oncology and Hematology, A.O.U of Modena-Policlinico, Modena, Italy.
Ljungström V; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Zucchini P; Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Forghieri F; Hematology Division, Department of Oncology and Hematology, A.O.U of Modena-Policlinico, Modena, Italy.
Potenza L; Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Ghia P; Division of Experimental Hematology, Laboratory of B cell Neoplasia, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy.
Marasca R; Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Trenti T; Department of Laboratory Medicine and Pathology, Unità Sanitaria Locale, Modena, Italy.
Tagliafico E; Center for Genome Research, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Luppi M; Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Aug; Vol. 62 (8), pp. 2018-2021. Date of Electronic Publication: 2021 Mar 04.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Cysteine*
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Adenine/analogs & derivatives ; Agammaglobulinaemia Tyrosine Kinase ; Drug Resistance, Neoplasm ; Humans ; Mutation ; Piperidines ; Protein Kinase Inhibitors/therapeutic use
Raport
Tytuł :
Epidemiology, treatment patterns and survival of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) in Taiwan, 2006-2015.
Autorzy :
Ko BS; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Chen LJ; Health Data Research Center, National Taiwan University, Taipei, Taiwan.; Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan.
Huang HH; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chen HM; Health Data Research Center, National Taiwan University, Taipei, Taiwan.; Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan.
Hsiao FY; Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan.; School of Pharmacy, National Taiwan University, Taipei, Taiwan.; Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.
Pokaż więcej
Źródło :
International journal of clinical practice [Int J Clin Pract] 2021 Aug; Vol. 75 (8), pp. e14258. Date of Electronic Publication: 2021 May 29.
Typ publikacji :
Journal Article
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/epidemiology
Adult ; Asia ; Humans ; Incidence ; Male ; Neoplasm Recurrence, Local ; Taiwan/epidemiology
Czasopismo naukowe
Tytuł :
Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia.
Autorzy :
Fresa A; Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
Autore F; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Innocenti I; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Piciocchi A; GIMEMA Foundation, Rome, Italy.
Tomasso A; Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
Morelli F; Haematology Unit, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy.
Sorà F; Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Sica S; Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
De Stefano V; Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Laurenti L; Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2021 Aug; Vol. 39 (3), pp. 423-427. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Letter
MeSH Terms :
Disseminated Intravascular Coagulation*/blood
Disseminated Intravascular Coagulation*/chemically induced
Leukemia, Lymphocytic, Chronic, B-Cell*/blood
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Antibodies, Monoclonal, Humanized/*adverse effects
Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Chlorambucil/administration & dosage ; Chlorambucil/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Platelet Count ; Retrospective Studies
Opinia redakcyjna
Tytuł :
Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.
Autorzy :
Baumann T; Department of Hematology, Hospital Clinic, University of Barcelona, Barcelona, Spain.; Servicio de Hematología, Hospital 12 de Octubre, Madrid, Spain.
Moia R; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Gaidano G; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Delgado J; Department of Hematology, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Condoluci A; Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Villamor N; Department of Pathology, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Payedimarri AB; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Costa D; Cancer Cytogenetics, Department of Pathology, Hospital Clinic, Barcelona, Spain.
Patriarca A; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Jiménez-Vicente C; Department of Hematology, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Rossi D; Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Montserrat E; Department of Hematology, Hospital Clinic, University of Barcelona, Barcelona, Spain. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Aug; Vol. 35 (8), pp. 2325-2331. Date of Electronic Publication: 2021 Feb 04.
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Immunotherapy/*methods
Leukemia, Lymphocytic, Chronic, B-Cell/*pathology
Lymphocytes/*pathology
Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; Lymphocytes/drug effects ; Lymphocytes/immunology ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma.
Autorzy :
Balakrishna J; Laboratory of Pathology, Department of Flow Cytometry, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.; Department of Hematopathology, Ohio State University Wexner Medical Center, Columbus, OH, USA.
Basumallik N; Hematology Branch, NHLBI, NIH, Bethesda, MD, USA.
Matulonis R; Walter Reed National Military Medical Center, Bethesda, MD, USA.
Scott D; Laboratory of Pathology, Department of Flow Cytometry, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Salem D; Laboratory of Pathology, Department of Flow Cytometry, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.; Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Jasper G; Laboratory of Pathology, Department of Flow Cytometry, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Wiestner A; Hematology Branch, NHLBI, NIH, Bethesda, MD, USA.
Stetler-Stevenson M; Laboratory of Pathology, Department of Flow Cytometry, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Marti G; Hematology Branch, NHLBI, NIH, Bethesda, MD, USA.
Sun C; Hematology Branch, NHLBI, NIH, Bethesda, MD, USA.
Yuan CM; Laboratory of Pathology, Department of Flow Cytometry, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Aug; Vol. 62 (8), pp. 1828-1839. Date of Electronic Publication: 2021 Mar 18.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Lymphocytosis*/diagnosis
Lymphocytosis*/genetics
B-Lymphocytes ; Humans ; Immunoglobulin Heavy Chains/genetics ; Mutation ; Prognosis
Czasopismo naukowe
Tytuł :
A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
Autorzy :
Chauzeix J; Laboratoire d'Hématologie et, UMR CNRS 7276/INSERM 1262, CRIBL, Centre de Biologie et de Recherche en Santé, CHU et Université de Limoges, Limoges, France.
Pastoret C; Inserm, MICMAC - UMR_S 1236, CHU Rennes, Université Rennes 1, Rennes, France.
Donaty L; Laboratoire d'Hématologie et, UMR CNRS 7276/INSERM 1262, CRIBL, Centre de Biologie et de Recherche en Santé, CHU et Université de Limoges, Limoges, France.
Gachard N; Laboratoire d'Hématologie et, UMR CNRS 7276/INSERM 1262, CRIBL, Centre de Biologie et de Recherche en Santé, CHU et Université de Limoges, Limoges, France.
Fest T; Inserm, MICMAC - UMR_S 1236, CHU Rennes, Université Rennes 1, Rennes, France.
Feuillard J; Laboratoire d'Hématologie et, UMR CNRS 7276/INSERM 1262, CRIBL, Centre de Biologie et de Recherche en Santé, CHU et Université de Limoges, Limoges, France.
Rizzo D; Laboratoire d'Hématologie et, UMR CNRS 7276/INSERM 1262, CRIBL, Centre de Biologie et de Recherche en Santé, CHU et Université de Limoges, Limoges, France.
Pokaż więcej
Źródło :
International journal of laboratory hematology [Int J Lab Hematol] 2021 Aug; Vol. 43 (4), pp. 683-692. Date of Electronic Publication: 2020 Dec 16.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Leukemia, Lymphocytic, Chronic, B-Cell*/mortality
Mutation*
Ataxia Telangiectasia Mutated Proteins/*genetics
Baculoviral IAP Repeat-Containing 3 Protein/*genetics
Karyopherins/*genetics
Myeloid Differentiation Factor 88/*genetics
Phosphoproteins/*genetics
RNA Splicing Factors/*genetics
Receptor, Notch1/*genetics
Receptors, Cytoplasmic and Nuclear/*genetics
Tumor Necrosis Factor alpha-Induced Protein 3/*genetics
Tumor Suppressor Protein p53/*genetics
Adult ; Aged ; Cost of Illness ; Female ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.
Autorzy :
Rigolin GM; Department of Medical Sciences, Hematology Section, University of Ferrara, Cona - Ferrara, Italy.
Cavazzini F; Department of Medical Sciences, Hematology Section, University of Ferrara, Cona - Ferrara, Italy.
Piciocchi A; GIMEMA Foundation, Rome, Italy.
Arena V; GIMEMA Foundation, Rome, Italy.
Visentin A; Department of Medicine, Hematology and Clinical Immunology Unit, University of Padua, Padua, Italy.
Reda G; Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Zamprogna G; Hematology, Niguarda Cancer Centre, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Cibien F; Hematology, Ospedale Ca' Foncello, Treviso, Italy.
Vitagliano O; Hematology, Cardarelli Hospital, Naples, Italy.
Coscia M; Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy.; Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
Farina L; Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Milano, Italy.
Gaidano G; Department of Translational Medicine, Division of Hematology, Università del Piemonte Orientale, Novara, Italy.
Murru R; Hematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, ARNAS 'G. Brotzu', Cagliari, Italy.
Varettoni M; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Paolini R; Hematology Unit, Rovigo General Hospital, Rovigo, Italy.
Sportoletti P; Department of Medicine and Surgery, Institute of Hematology and Centre for Hemato-Oncological Research, Ospedale S. Maria della Misericordia, Perugia, Italy.
Pietrasanta D; Hematology Division, Dipartimento Internistico Struttura Complessa di Ematologia Ospedale civile SS Antonio e Biagio, Alessandria, Italy.
Molinari AL; Hematology, Ospedale degli Infermi, Rimini, Italy.
Quaglia FM; Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Laurenti L; Fondazione Policlinico Universitario A Gemelli. Roma IRCCS, Rome, Italy.
Marasca R; Department of Medical and Surgical Sciences, Section of Hematology, University of Modena and Reggio Emilia, Modena, Italy.
Marchetti M; Oncology Unit, Cardinal Massaia Hospital, Asti, Italy.
Mauro FR; Department of Translational and Precision Medicine, Hematology, 'Sapienza' University, Rome, Italy.
Crea E; GIMEMA Foundation, Rome, Italy.
Vignetti M; GIMEMA Foundation, Rome, Italy.
Gentile M; Department of Onco-Hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy.
Montillo M; Hematology, Niguarda Cancer Centre, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Foà R; Department of Translational and Precision Medicine, Hematology, 'Sapienza' University, Rome, Italy.
Cuneo A; Department of Medical Sciences, Hematology Section, University of Ferrara, Cona - Ferrara, Italy.
Pokaż więcej
Corporate Authors :
GIMEMA Group
Źródło :
Hematological oncology [Hematol Oncol] 2021 Aug; Vol. 39 (3), pp. 326-335. Date of Electronic Publication: 2021 Mar 26.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell/*mortality
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Disease-Free Survival ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Male ; Middle Aged ; Purines/administration & dosage ; Purines/adverse effects ; Quinazolinones/administration & dosage ; Quinazolinones/adverse effects ; Recurrence ; Rituximab/administration & dosage ; Rituximab/adverse effects ; Survival Rate
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies